TransMedics Group, Inc.
70.74USD
-1.3200 (-1.83%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on TMDX.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 93.5M | 241.6M | 441.5M | 605.5M | 742.2M | 874.7M |
| Q1 | 15.9M | 41.6M | 96.9M | 143.5M | 173.9M | — |
| Q2 | 20.5M | 52.5M | 114.3M | 157.4M | 189.9M | — |
| Q3 | 24.3M | 66.4M | 108.8M | 143.8M | 178.1M | — |
| Q4 | 32.8M* | 81.2M* | 121.6M* | 160.8M* | 201.3M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -1.23 | -.770 | 1.01 | 4.87 | 1.51 | 2.25 |
| Q1 | -.380 | -.080 | .350 | .700 | .200 | — |
| Q2 | -.410 | -.030 | .350 | .920 | .410 | — |
| Q3 | -.250 | -.780 | .120 | .660 | .293 | — |
| Q4 | -.227* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| .124* |
| .195* |
| 2.60* |
| .499 |
| — |
Debt level and coverage